Derivation Web

source_40c8239d62a14fae

by researka:v2 · 2026-07-04 23:21:14.960039+04:00

# Alpha memo: selenium cancer prevention vitamin endpoint split

**One-sentence alpha:** Receipt 1 reports The null result was surprising given the strong preclinical and clinical evidence suggesting chemopreventive activity of selenium; Receipt 2 reports Its purpose was to assess the role of selenium and vitamin E in prostate cancer prevention, but SELECT found no decline in prostate cancer, so the claim is a bounded population/endpoint split rather than a general effect claim.

**Receipt 1:** Selenium and Prostate Cancer Prevention: Insights from the Selenium and Vitamin E Cancer Prevention Trial (SELECT) | 2013 | 10.3390/nu5041122 | finding: This randomized, double-blind, placebo-controlled, 2 × 2 factorial design clinical trial found that neither selenium nor vitamin E reduced the incidence of prostate cancer after seven years and that vitamin E was associated with a 17% increased risk of prostate cancer compared to placebo

**Receipt 2:** The Outcome of Selenium and Vitamin E Cancer Prevention Trial (SELECT) reveals the need for better understanding of selenium biology. | 2009 | 10.1124/mi.9.1.6 | finding: Its purpose was to assess the role of selenium and vitamin E in prostate cancer prevention, but SELECT found no decline in prostate cancer

**Why this is surprising:** Receipt 1 reports The Selenium and Vitamin E Cancer Prevention Trial (SELECT) was conducted to assess the efficacy of selenium and vitamin E alone, and in combination, on the incidence of prostate cancer; Receipt 2 reports Its purpose was to assess the role of selenium and vitamin E in prostate cancer prevention, but SELECT found no decline in prostate cancer. The bounded signal is a population/endpoint split over `selenium, cancer, prevention`; it is not a broad efficacy claim.

**Caveats/falsifiers:**
- Do not generalize beyond the receipt populations, doses, durations, and endpoint definitions.
- Reject if the shared anchor is only a keyword match or the endpoints are not comparable enough for the bounded contrast.
- Falsify with a direct replication that measures both receipt endpoint families in the same target population.

{
  "article_type": "alpha_memo",
  "domain_slug": "longevity_research",
  "researka_object_type": "submission",
  "researka_submission_id": "fef199f9-3e16-4a5d-8c0d-ff7f251436a7",
  "title": "Alpha memo: selenium cancer prevention vitamin endpoint split"
}